Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1994 1
1995 4
1996 2
1997 4
1998 4
1999 3
2000 5
2001 4
2002 6
2003 4
2004 11
2005 18
2006 9
2007 25
2008 34
2009 52
2010 49
2011 55
2012 78
2013 57
2014 57
2015 62
2016 63
2017 64
2018 53
2019 58
2020 70
2021 100
2022 88
2023 83
2024 24

Text availability

Article attribute

Article type

Publication date

Search Results

1,001 results

Results by year

Filters applied: . Clear all
Page 1
CAR T-cell therapy in autoimmune diseases.
Schett G, Mackensen A, Mougiakakos D. Schett G, et al. Lancet. 2023 Nov 25;402(10416):2034-2044. doi: 10.1016/S0140-6736(23)01126-1. Epub 2023 Sep 22. Lancet. 2023. PMID: 37748491 Review.
Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus.
Mackensen A, Müller F, Mougiakakos D, Böltz S, Wilhelm A, Aigner M, Völkl S, Simon D, Kleyer A, Munoz L, Kretschmann S, Kharboutli S, Gary R, Reimann H, Rösler W, Uderhardt S, Bang H, Herrmann M, Ekici AB, Buettner C, Habenicht KM, Winkler TH, Krönke G, Schett G. Mackensen A, et al. Among authors: schett g. Nat Med. 2022 Oct;28(10):2124-2132. doi: 10.1038/s41591-022-02017-5. Epub 2022 Sep 15. Nat Med. 2022. PMID: 36109639
CD19-Targeted CAR T Cells in Refractory Systemic Lupus Erythematosus.
Mougiakakos D, Krönke G, Völkl S, Kretschmann S, Aigner M, Kharboutli S, Böltz S, Manger B, Mackensen A, Schett G. Mougiakakos D, et al. Among authors: schett g. N Engl J Med. 2021 Aug 5;385(6):567-569. doi: 10.1056/NEJMc2107725. N Engl J Med. 2021. PMID: 34347960 No abstract available.
Enthesitis: from pathophysiology to treatment.
Schett G, Lories RJ, D'Agostino MA, Elewaut D, Kirkham B, Soriano ER, McGonagle D. Schett G, et al. Nat Rev Rheumatol. 2017 Nov 21;13(12):731-741. doi: 10.1038/nrrheum.2017.188. Nat Rev Rheumatol. 2017. PMID: 29158573 Review.
EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update.
Gossec L, Baraliakos X, Kerschbaumer A, de Wit M, McInnes I, Dougados M, Primdahl J, McGonagle DG, Aletaha D, Balanescu A, Balint PV, Bertheussen H, Boehncke WH, Burmester GR, Canete JD, Damjanov NS, Kragstrup TW, Kvien TK, Landewé RBM, Lories RJU, Marzo-Ortega H, Poddubnyy D, Rodrigues Manica SA, Schett G, Veale DJ, Van den Bosch FE, van der Heijde D, Smolen JS. Gossec L, et al. Among authors: schett g. Ann Rheum Dis. 2020 Jun;79(6):700-712. doi: 10.1136/annrheumdis-2020-217159. Ann Rheum Dis. 2020. PMID: 32434812 Free PMC article.
CD19-targeted CAR T cells in refractory antisynthetase syndrome.
Müller F, Boeltz S, Knitza J, Aigner M, Völkl S, Kharboutli S, Reimann H, Taubmann J, Kretschmann S, Rösler W, Manger B, Wacker J, Mougiakakos D, Jabari S, Schröder R, Uder M, Roemer F, Krönke G, Mackensen A, Schett G. Müller F, et al. Among authors: schett g. Lancet. 2023 Mar 11;401(10379):815-818. doi: 10.1016/S0140-6736(23)00023-5. Epub 2023 Feb 15. Lancet. 2023. PMID: 36930673 No abstract available.
Psoriatic arthritis from a mechanistic perspective.
Schett G, Rahman P, Ritchlin C, McInnes IB, Elewaut D, Scher JU. Schett G, et al. Nat Rev Rheumatol. 2022 Jun;18(6):311-325. doi: 10.1038/s41584-022-00776-6. Epub 2022 May 5. Nat Rev Rheumatol. 2022. PMID: 35513599 Review.
1,001 results